Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells

• US 20060292695A1
• Filed: 09/22/2005
• Published: 12/28/2006
• Est. Priority Date: 06/22/2005
• Status: Abandoned Application

• Current Assignee: CXR Biosciences Ltd. (Concept Life Sciences (Midco) Ltd.)
• Original Assignee: CXR Biosciences Ltd. (Concept Life Sciences (Midco) Ltd.), Roslin Institute
• Inventors: Clark, A. John, Wolf, C. Roland, Clark, Helen
• Application Number:
  US11/233,819
• Publication Number:
  US 20060292695A1
• Time in Patent Office: Days
• US Class Current: 435/370
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2503/02 Drug screening
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/067 Hepatocytes
• CPC Class Codes: C12Q 1/26 involving oxidoreductase
• CPC Class Codes: C12Q 1/48 involving transferase
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/5058 Neurological cells
• CPC Class Codes: G01N 33/5061 Muscle cells
• CPC Class Codes: G01N 33/5067 Liver cells
• CPC Class Codes: G01N 33/5073 Stem cells
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

This invention provides a system for rapid determination of pharmacologic effects on target tissue types in cell populations cultured in vitro. The cells contain a promoter-reporter construct that reflects a toxicologic or metabolic change caused by the agent being screened. The promoter is taken from a gene known to be up- or down-regulated according to the metabolic state of the cell, and linked to a reporter gene that provides an external signal for monitoring promoter activity. The promoter-reporter cells may be produced by placing these genetic alterations into a line of human embryonic stem cells, bulking up the cells to any extent desired, and then differentiating the cells into the desired tissue type. This disclosure explains some of the powerful features of the promoter-reporter cells of this invention, and shows various ways the skilled reader can use the invention for pharmaceutical development and testing, or to monitor graft survival.

Claims

1. A method of drug testing, comprising:

a) combining the drug with a cell population differentiated from human embryonic stem (hES) cells, comprising cells that have been genetically altered so that a promoter that responds to a metabolic or toxicologic change in the cell controls expression of a reporter gene; and

then

b) determining whether there is a change in expression of the reporter gene.

2. The method of claim 1, wherein the cell population is a population of neural, cardiomyocyte, or hepatocyte lineage cells.

3. The method of claim 1, wherein the promoter responds to apoptosis, DNA damage, hyperplasia, oxidative stress, or a metabolic or toxicologic change in the cell.

4. The method of claim 1, wherein the promoter is a promoter for a gene selected from PUMA, p21, p21WAF1, Ki-67, heme oxygenase 1, superoxide dismutase, γ

-glutamyl cysteinyl ligase, metallothionine, PXR, CAR, aryl hydrocarbon receptor (AhR), Nrf2 gene, prostate specific antigen, MDR1, CYP3A4, and CYP1A1.

5. The method of claim 1, wherein the cell population has also been genetically altered so that a second promoter that is tissue specific controls expression of a second reporter gene.

6. The method of claim 5, wherein the second promoter is a promoter for a hepatocyte specific marker selected from albumin, α

1-antitrypsin, α

-fetoprotein, γ

-glutamyl tranpeptidase, glucose-6-phosphatase, catalase, and monooxygenase.

7. The method of claim 5, comprising determining whether there is a change in expression of the first reporter gene in cells expressing the second reporter gene.

8. The method of claim 1, wherein the cells have been genetically altered to express a gene encoding a variant of an endogenous drug target or drug metabolizing enzyme.

9. The method of claim 1, wherein the cell population has been obtained by:

i) genetically altering cells from said hES cell line, thereby producing hES cells in which a promoter that responds to a metabolic or toxicologic change in the cell controls expression of a reporter gene;

ii) proliferating the genetically altered hES cells to form a genetically altered hES cell population; and

then

iii) differentiating the genetically altered hES cell population into a population of genetically altered differentiated cells.

10. The method of claim 1, comprising combining the drug with the cell population in the presence or absence of an RNAi for a drug target or drug metabolizing enzyme, and determining whether there is a difference in expression of the reporter gene in the presence of the drug with or without the RNAi.

11. A system or kit for drug testing according to the method of claim 1, comprising a cell population differentiated from human embryonic stem (hES) cells, in which at least some of the cells have been genetically altered so that a promoter that responds to a metabolic or toxicologic change in the cell controls expression of a reporter gene.

12. The system or kit of claim 11, further comprising a compound known to change expression of the reporter gene in the cells.

13. The system or kit of claim 11, comprising a plurality of cell populations sharing the same genome, but genetically altered such that different promoters that respond to a metabolic or toxicologic change control expression of a reporter gene in each cell population.

14. The system or kit of claim 11, comprising a plurality of cell populations sharing the same genome, but differentiated into cells of different tissues.

15. The system or kit of claim 11, comprising a plurality of promoter-reporter cell populations sharing the same genome, but having different variants of said drug target or drug metabolizing enzyme.

16. The system or kit of claim 11, wherein the variants are allelic variants of CYP2D6, CYP2C9, CYP2C1 g, N-acetyl transferase, or thiopurine methyltransferase.

17. Isolated tissue prepared for transplantation and adapted for monitoring after engraftment into a subject, containing cells differentiated from hES cells that have been genetically altered so that a promoter that responds to a metabolic or toxicologic change in the cell controls expression of a reporter gene.

18. The isolated tissue of claim 17, wherein the reporter gene in the promoter-reporter cell population encodes an excretable reporter.

19. The isolated tissue of claim 18, wherein the excretable reporter is hCG.

20. A method for evaluating a tissue allograft in a subject, comprising grafting the subject with tissue according to claim 17, and monitoring the tissue after engraftment by expression of the reporter gene.